Chronic myeloid leukemia (CML) can transform into a disease that closely resembles acute myeloid leukemia (AML), and this shift is one of the most serious complications a CML patient can face. This transformation is called “blast crisis” or “blast phase,” and it occurs when immature blood cells (blasts) make up 20% or more of the blood or bone marrow. With modern targeted therapies, the risk is much lower than it used to be, but it still happens in roughly 5 to 6% of patients over ten years.
What Blast Crisis Actually Means
CML normally progresses through phases. In the chronic phase, the disease is slow-moving and manageable. If it worsens, it enters an accelerated phase, where immature blast cells rise to between 10% and 19% of the blood or bone marrow. When blasts hit 20% or higher, the disease has entered blast phase, also called blast crisis. At that point, the leukemia behaves like an acute leukemia rather than a chronic one.
About 70 to 80% of blast crisis cases are myeloid, meaning they look and act like AML. The remaining 20 to 30% are lymphoid, resembling acute lymphoblastic leukemia (ALL) instead. So while CML doesn’t literally “become” AML in the way one disease converts into another, the myeloid version of blast crisis is so similar to AML that it’s treated as an AML-like emergency. The distinction matters because blast-phase CML still carries the original genetic abnormality (the Philadelphia chromosome) that defines CML, even as it takes on the aggressive character of acute leukemia.
Why the Transformation Happens
CML is driven by an abnormal gene called BCR-ABL1, created when two chromosomes swap pieces of DNA. This gene produces a protein that pushes white blood cells to multiply out of control. In the chronic phase, the cells still mature somewhat normally. The trouble starts when leukemia stem cells accumulate additional genetic damage on top of the original BCR-ABL1 problem.
This is sometimes called a “second hit.” The BCR-ABL1 gene itself causes DNA instability, making the cells prone to copying errors. Over time, those errors pile up. Key genes that normally suppress tumors or guide cells to mature properly get knocked out. The p53 gene, one of the body’s most important tumor-suppressing genes, is frequently lost or mutated in blast crisis. Another gene called RUNX1 (sometimes called AML1, because of its strong link to acute leukemia) is mutated in 13 to 33% of patients with advanced-phase CML. When RUNX1 malfunctions, it blocks normal blood cell maturation and accelerates the shift toward blast crisis.
At the same time, the activity of the BCR-ABL1 protein itself tends to increase. Higher levels of this protein impair the ability of early blood cells to mature into functional white blood cells. The combination of rising BCR-ABL1 activity and accumulating genetic damage creates the conditions for a clone of immature blast cells to take over.
How Common Is This Progression Today?
Before targeted therapies (tyrosine kinase inhibitors, or TKIs) became available in the early 2000s, about 20% of CML patients developed a sudden blast crisis with no warning signs of an accelerated phase first. The introduction of TKIs dramatically changed that picture. The 10-year blast transformation rate is now only 5 to 6%.
When blast crisis does occur in patients on TKI therapy, it typically happens in the first one to two years of treatment. These early transformations are thought to result from genetic changes that were already in motion before treatment started, meaning the TKI didn’t have time to stabilize the disease. After those initial years, the risk drops significantly. Sudden blast crisis in a well-treated patient is now uncommon, occurring in roughly 1 to 2% of cases.
Warning Signs of Progression
The transition from chronic phase to blast crisis can happen gradually over a year or more, or it can arrive abruptly. In many cases, an accelerated phase comes first, with signs that include worsening anemia, rising white blood cell counts that don’t respond to treatment, increasing platelet counts, and a progressively enlarging spleen.
When blast crisis itself sets in, the symptoms intensify. Patients often experience:
- Dropping platelet counts, which can lead to easy bruising or bleeding
- A painful, rapidly enlarging spleen or liver
- Persistent fever not caused by infection
- Bone pain, sometimes with destructive bone lesions visible on imaging
- Fatigue and general malaise that worsens noticeably over days to weeks
These changes show up in blood work as a sharp rise in blast cells. Regular blood monitoring is one of the main reasons CML patients have frequent lab appointments. Catching a rise in blast percentage early, before it crosses the 20% threshold, gives doctors more room to adjust treatment.
How Blast-Phase CML Is Treated
Blast-phase CML is significantly harder to treat than chronic-phase CML. Because the myeloid form resembles AML, treatment often combines TKI therapy with intensive chemotherapy similar to what AML patients receive. For the lymphoid form, treatment follows protocols closer to those used for ALL.
For patients who respond well enough to initial treatment, an allogeneic stem cell transplant (using donor cells) is often the next step. Transplant remains the only approach with a realistic chance of long-term remission once blast crisis has occurred. Without transplant, responses to chemotherapy and TKIs in blast phase tend to be short-lived.
Survival After Blast Transformation
The prognosis for blast-phase CML is sobering. Median overall survival after transformation is roughly four months in real-world data. Notably, patients whose CML progressed from the chronic phase into blast crisis tend to fare worse than those who present in blast phase from the start, with a median survival of about three months compared to nine months for those diagnosed in blast phase without a prior chronic phase history.
These numbers underscore why preventing blast crisis in the first place is the central goal of CML treatment. Patients who take their TKI consistently and achieve a deep molecular response have a very low risk of ever reaching this stage. The gap between the 20% blast crisis rate in the pre-TKI era and the 5 to 6% rate today reflects one of the most dramatic improvements in cancer treatment over the past two decades.